Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4271 results
Redx Pharma reaches pre-clinical proof of concept stage with oncology lead
Redx Pharma has reached pre-clinical proof of concept stage with an oncology lead that has the potential to treat leukaemia and other blood cancers.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, BioMed X start project to identify new treatment approaches for psychiatric diseases
By PBR Staff Writer
Boehringer Ingelheim and BioMed X have started a new project to identify and develop novel treatment approaches for psychiatric diseases.
Drug Research > Drug Discovery & Development > News
Avalon Ventures, COI form PDI Therapeutics to develop novel immune-oncology therapies
By PBR Staff Writer
Avalon Ventures and COI Pharmaceuticals have established PDI Therapeutics to develop novel immune-oncology therapies.
Drug Research > Drug Discovery & Development > News
Acorda to stop Plumiaz development to treat epilepsy seizure clusters
By PBR Staff Writer
Acorda Therapeutics said it will stop the development of its Plumiaz (diazepam) Nasal Spray for the treatment of epilepsy seizure clusters due to disappointing data from ongoing clinical trials.
Drug Research > Drug Discovery & Development > News
Amgen researchers discover gene variation that lowers heart attack risk
By PBR Staff Writer
Researchers from Amgen's deCODE genetics subsidiary have discovered a rare genetic variation that reduces cholesterol levels and heart attack risk in some people.
Drug Research > Drug Discovery & Development > News
Mitochon Pharmaceuticals raises $1.6m for clinical stage development
Mitochon Pharmaceuticals has completed its second year of funding with a total investment of $1.6m.
Drug Research > Drug Discovery & Development > News
Catalyst Pharmaceuticals announces 30% reduction in workforce
Catalyst Pharmaceuticals, which is focused on developing and commercializing new therapies for people with rare debilitating diseases, is reducing its workforce by approximately 30%.
Drug Research > Drug Discovery & Development > News
Agios, Celgene agree to establish metabolic immuno-oncology alliance
By CBR Staff Writer
Agios Pharmaceuticals and Celgene have signed an agreement to establish a new global collaboration focused on metabolic immuno-oncology.
Drug Research > Drug Discovery & Development > News
Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal
By PBR Staff Writer
Pfizer has agreed to acquire Anacor Pharmaceuticals in a transaction valued at about $5.2bn.
Drug Research > Drug Discovery & Development > News
Five Prime advances FPA008 into phase 2 dose expansion in PVNS patients
Five Prime Therapeutics has advanced FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
Drug Research > Drug Discovery & Development > News
Aegerion reaches preliminary agreements in principle with DOJ and SEC over ongoing investigations
Aegerion Pharmaceuticals has reached preliminary agreements in principle with the Department of Justice (DOJ) and the staff of the Securities and Exchange Commission (SEC) regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID (lomitapide) capsules ("JUXTAPID").
Drug Research > Drug Discovery & Development > News
Tetraphase Pharmaceuticals offers update on eravacycline regulatory and development status
Tetraphase Pharmaceuticals has received guidance from the U.S. Food and Drug Administration (FDA) regarding the regulatory path of the Company's lead candidate, eravacycline, an antibiotic with potent activity against drug-resistant bacteria, including MDR pathogens highlighted as urgent public health threats by the CDC.
Drug Research > Drug Discovery & Development > News
G1 Therapeutics secures $47m Series C financing
Clinical-stage oncology company G1 Therapeutics has completed a $47m Series C financing led by new investor Cormorant Asset Management.
Drug Research > Drug Discovery & Development > News
Taiho Pharmaceutical establishes Taiho Ventures to support oncology biotech start-ups
Taiho Pharmaceutical (TPC) has established Taiho Ventures, a strategic corporate venture capital arm of TPC, in California, US.
Drug Research > Drug Discovery & Development > News
Aptinyx raises $65m for neurological disorder drugs
By PBR Staff Writer
US-based biopharmaceutical firm Aptinyx has raised $65m in Series A financing to advance therapies for neurological disorders.
Drug Research > Drug Discovery & Development > News
91-105 of 4271 results